RSCM
INDV icon

Rock Springs Capital Management’s Indivior Pharmaceuticals INDV Stock Holding History

Rock Springs Capital Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Buy
245,500
+45,500
+23% +$1.65M 0.49% 57
2026
Q1 		$6.1M Buy
200,000
+94,900
+90% +$3.13M 0.36% 62
2025
Q4 		$3.77M Buy
+105,100
New +$3.21M 0.19% 83

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rock Springs Capital Management's INDV Position: Q2 2026 in Review

Rock Springs Capital Management increased its Indivior Pharmaceuticals (INDV) stake by 23% in Q2 2026, buying an estimated $1.65M and bringing the position to 245,500 shares worth $10.1M. The position accounts for 0.49% of the portfolio, ranked #57.

Rock Springs Capital Management first reported a position in INDV in Q4 2025 and has held it in 3 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Rock Springs Capital Management held 245,500 shares of Indivior Pharmaceuticals worth $10.1M as of Q2 2026.
  • Rock Springs Capital Management bought 45,500 Indivior Pharmaceuticals shares in Q2 2026, an estimated $1.65M.
  • Indivior Pharmaceuticals made up 0.49% of Rock Springs Capital Management's portfolio in Q2 2026, its #57 holding.
  • Rock Springs Capital Management first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.